Trial Profile
A Phase 2 Trial Using Gilotrif for Advanced Penile Squamous Cell Carcinoma Following Systemic Therapy
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 15 Apr 2020
Price :
$35
*
At a glance
- Drugs Afatinib (Primary)
- Indications Penile cancer; Squamous cell cancer
- Focus Therapeutic Use
- 12 Feb 2020 Status changed from recruiting to discontinued.
- 30 Nov 2018 Planned primary completion date changed from 1 Oct 2018 to 1 Jan 2019.
- 12 Nov 2015 Planned primary completion date changed from 1 Sep 2018 to 1 Oct 2018, as reported by ClinicalTrials.gov.